Author: paroukatos

Taro E. Akiyama, PhD,* Peter T. Meinke, PhD, and Joel P. Berger, PhD Metabolic syndrome (MS), a condition characterized by multiple related clinical disorders including insulin resistance, central obesity, hyperlipidemia, hypertension, and heart disease, is an increasingly prevalent disease in industrialized societies. The intense research interest...

Alexander Tenenbaum*1,2, Enrique Z Fisman1,2 and Michael Motro1,2 Abstract The metabolic syndrome is a highly prevalent clinical entity. The recent Adult Treatment Panel (ATP III) guidelines have called specific attention to the importance of targeting the cardiovascular risk factors of the metabolic syndrome as a method of...

Yau-Sheng Tsai,1 Hyo-Jeong Kim,2 Nobuyuki Takahashi,1 Hyung-Suk Kim,1 John R. Hagaman,1 Jason K. Kim,2 and Nobuyo Maeda1 1Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. 2Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale University School of Medicine, New...

Hazel A. Bradleya, Charles Shey Wiysongeb, Jimmy A. Volminkc, Bongani M. Mayosib and Lionel H. Opied  Objective To quantify the effect of first-line antihypertensive treatment with beta-blockers on mortality, morbidity and withdrawal rates, compared with the other main classes of antihypertensive agents. Methods We identified eligible trials by searching...

Anthony H. Barnett, M.D., Stephen C. Bain, M.D., Paul Bouter, Ph.D., Bengt Karlberg, M.D., Sten Madsbad, M.D., Jak Jervell, Ph.D.,  and Jukka Mustonen, Ph.D., for the Diabetics Exposed to Telmisartan and Enalapril Study Group* background: Few studies have directly compared the renoprotective effects of angiotensin II-receptor...

George C. Sutton a, Jan Erik Otterstad b, Bridget-Anne Kirwan c, Zoltán Vokó d, Sophie de Brouwer c, Jacobus Lubsen c,e, Philip A. Poole-Wilson a,⁎ On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators Cardiac Medicine, National Heart and Lung Institute, Imperial College...

ohn J.V. McMurray, MB, MD,a James B. Young, MD,b Mark E. Dunlap, MD,c Christopher B. Granger, MD,d James Hainer, MD,e Eric L. Michelson, MD,e Steven Earle, PhD,e Bertil Olofsson, PhD,f Jan O¨ stergren, MD,g Salim Yusuf, MD, DPhil,h Karl Swedberg, MD, PhD,i and Marc A....

Norman M. Kaplan At least in hypertension, there has never been a perfect clinical trial. By its nature, hypertension poses several barriers to the performance and interpretation of even the most carefully planned and conducted therapeutic trial. First and perhaps foremost, blood pressure is a constantly...

Thomas Giles Ambulatory blood pressure monitoring enables the recording of the circadian rhythm of blood pressure under everyday circumstances, with the majority of individuals displaying diurnal variations in both systolic and diastolic blood pressures. During sleep, blood pressure in most people is between 10% and 20%...